NDAINHALATIONSOLUTION
Approved
Nov 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
3
Data completeness
5/8 — Partial
YUPELRI (revefenacin) by Viatris (2) is cholinergic antagonists [moa]. First approved in 2018.
Drug data last refreshed 4h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
YUPELRI (revefenacin) is a long-acting muscarinic antagonist (LAMA) delivered via inhalation solution for maintenance treatment of chronic obstructive pulmonary disease (COPD). It works by blocking cholinergic receptors in airway smooth muscle to improve bronchodilation and reduce airflow obstruction. This anticholinergic agent represents a once-daily maintenance therapy option for COPD patients.
$0.004BPart D
Peak13.3 years to LOEProduct is at peak lifecycle stage with modest Part D uptake (3,868 claims, $4M spending in 2023), suggesting a niche market position with stable but limited team growth.
Mechanism of Action
Cholinergic Antagonists
Pharmacologic Class:
Anticholinergic
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Revefenacin in Acute Respiratory Insufficiency in COPD
Started Nov 2020
21 enrolled
COPDAcute Respiratory Failure
A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD
Started May 2018
122 enrolled
Chronic Obstructive Pulmonary Disease (COPD)
Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD
Started Mar 2017
207 enrolled
Chronic Obstructive Pulmonary Disease, COPDLow Peak Inspiratory Flow Rate (PIFR)
Career Relevance
Working on YUPELRI offers exposure to a stable, niche respiratory product with strong patent protection but limited market growth and modest sales infrastructure. This role is best suited for professionals seeking a maintenance-phase product experience with lower-intensity commercial pressure compared to primary care therapeutics.
Worked on YUPELRI at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.